TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.

MLA

Spear, Timothy T., et al. “TCR Gene-Modified T Cells Can Efficiently Treat Established Hepatitis C-Associated Hepatocellular Carcinoma Tumors.” Cancer Immunology, Immunotherapy : CII, vol. 65, no. 3, Mar. 2016, pp. 293–304. EBSCOhost, https://doi.org/10.1007/s00262-016-1800-2.

APA

Spear, T. T., Callender, G. G., Roszkowski, J. J., Moxley, K. M., Simms, P. E., Foley, K. C., Murray, D. C., Scurti, G. M., Li, M., Thomas, J. T., Langerman, A., Garrett-Mayer, E., Zhang, Y., & Nishimura, M. I. (2016). TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunology, Immunotherapy : CII, 65(3), 293–304. https://doi.org/10.1007/s00262-016-1800-2

Chicago

Spear, Timothy T, Glenda G Callender, Jeffrey J Roszkowski, Kelly M Moxley, Patricia E Simms, Kendra C Foley, David C Murray, et al. 2016. “TCR Gene-Modified T Cells Can Efficiently Treat Established Hepatitis C-Associated Hepatocellular Carcinoma Tumors.” Cancer Immunology, Immunotherapy : CII 65 (3): 293–304. doi:10.1007/s00262-016-1800-2.